Details for Patent: 9,763,953
✉ Email this page to a colleague
Which drugs does patent 9,763,953 protect, and when does it expire?
Patent 9,763,953 protects ZUNVEYL and is included in one NDA.
This patent has fourteen patent family members in thirteen countries.
Summary for Patent: 9,763,953
| Title: | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| Abstract: | The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments. |
| Inventor(s): | Maelicke Alfred |
| Assignee: | NEURODYN LIFE SCIENCES INC. |
| Application Number: | US13861134 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,763,953
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-003 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,763,953
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E473219 | ⤷ Sign Up | |||
| Canada | 2623114 | ⤷ Sign Up | |||
| China | 101287719 | ⤷ Sign Up | |||
| Cyprus | 1110822 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
